Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes

Recent developments in myelodysplastic syndromes

(2014) R. Bejar et al.   BLOOD

An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin

(2014) Soraya Carrancio et al.   BRITISH JOURNAL OF HAEMATOLOGY

Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage study

(2014) Zoe K. McQuilten et al.   CANCER

Trends in incidence, initial treatment and survival of myelodysplastic syndromes: A population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010

(2014) Avinash G. Dinmohamed et al.   EUROPEAN JOURNAL OF CANCER

Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

(2014) Thomas Prebet et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

(2013) L. Malcovati et al.   BLOOD

New Strategies in Myelodysplastic Syndromes: Application of Molecular Diagnostics to Clinical Practice

(2013) Z. Tothova et al.   CLINICAL CANCER RESEARCH

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

(2013) H Yang et al.   LEUKEMIA

Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes

(2013) W. W. Pang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Epidemiology of Myelodysplastic Syndromes

(2012) Xiaomei Ma   AMERICAN JOURNAL OF MEDICINE

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

(2012) P. L. Greenberg et al.   BLOOD

New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

(2012) Julie Schanz et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

(2012) Azra Raza et al.   Journal of Hematology & Oncology

Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome

(2012) Naomi Galili et al.   Journal of Hematology & Oncology

A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome

(2011) Azra Raza et al.   CANCER

Oral ezatiostat HCl (Telintra®, TLK199) and Idiopathic Chronic Neutropenia (ICN): a case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP1-1) inhibitor

(2011) Roger M Lyons et al.   Journal of Hematology & Oncology

Incidence of myelodysplastic syndromes in a Swedish population

(2010) Anders Rådlund et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial

(2010) T. de Witte et al.   HAEMATOLOGICA

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines

(2010) Paul W. Hollenbach et al.   PLoS One

Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome

(2009) A. Raza et al.   BLOOD

Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)

(2009) P. L. Greenberg et al.   BLOOD

Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial

(2009) David P. Steensma et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra(R), TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome

(2009) Azra Raza et al.   Journal of Hematology & Oncology

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

(2009) S. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA